Phathom Pharmaceuticals, which operates in the Zacks Medical - Biomedical and Genetics industry, has been noted for underperforming the S&P 500 so far this year.
1 report, 1 independent
Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Phathom Pharmaceuticals, which operates in the Zacks Medical - Biomedical and Genetics industry, has been noted for underperforming the S&P 500 so far this year.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Coverage
Newest first; wire copies grouped- ZacksPhathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate